keyword
MENU ▼
Read by QxMD icon Read
search

Oxaliplatin

keyword
https://www.readbyqxmd.com/read/28922727/the-relevance-of-gastric-cancer-biomarkers-in-prognosis-and-pre-and-post-chemotherapy-in-clinical-practice
#1
REVIEW
Muhammad Abbas, Murad Habib, Muhammad Naveed, Kumaragurubaran Karthik, Kuldeep Dhama, Meiqi Shi, Chen Dingding
Gastric cancer (GC) is one among the major cancer types, causing human deaths and present noticeable heterogeneity. The incidences and mortality rates are higher in males in comparison to females with a male to female ratio of 2.3:1. A lot of studies have revealed out the molecular basis, pathogenesis, invasion and metastasis related findings of gastric stomach cancer. Present review encompasses the salient information on various biomarkers for the early diagnosis, treatment and prognosis of gastric cancer elaborate the clinical importance of serum tumor markers in patients with this cancer as well as checking the growths, together with epigenetic changes and genetic polymorphisms...
September 14, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28917648/challenges-of-conducting-a-prospective-clinical-trial-for-older-patients-lessons-learned-from-ncctg-n0949-alliance
#2
Nadine J McCleary, Joleen Hubbard, Michelle R Mahoney, Jeffrey A Meyerhardt, Daniel Sargent, Alan Venook, Axel Grothey
OBJECTIVES: While the risk of developing colorectal cancer increases with age, there are limited prospective data regarding best treatment in the older adult population. We launched a phase III trial to evaluate difference in treatment outcome for older adults (aged ≥70years) with advanced colorectal cancer. Here we review the challenges faced and reasons for poor accrual to N0949. MATERIALS AND METHODS: We describe the conceptualization, development and limited results of N0949, a randomized phase III study of fluoropyrimidine/bevacizumab with or without oxaliplatin (mFOLFOX7 or XELOX) as first line chemotherapy for metastatic colorectal cancer...
September 13, 2017: Journal of Geriatric Oncology
https://www.readbyqxmd.com/read/28911067/maintenance-treatment-with-capecitabine-and-bevacizumab-versus-observation-in-metastatic-colorectal-cancer-updated-results-and-molecular-subgroup-analyses-of-the-phase-3-cairo3-study
#3
K K H Goey, S G Elias, H van Tinteren, M M Laclé, S M Willems, G J A Offerhaus, W W J de Leng, E Strengman, A J Ten Tije, G-J M Creemers, A van der Velden, F E de Jongh, F L G Erdkamp, B C Tanis, C J A Punt, M Koopman
Background: The phase 3 CAIRO3 study showed that capecitabine plus bevacizumab (CAP-B) maintenance treatment after six cycles capecitabine, oxaliplatin, and bevacizumab (CAPOX-B) in metastatic colorectal cancer (mCRC) patients is effective, without compromising quality of life. In this post hoc analysis with updated follow-up and data regarding sidedness, we defined subgroups according to RAS/BRAF mutation status and mismatch repair (MMR) status, and investigated their influence on treatment efficacy...
September 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28906589/neoadjuvant-therapy-of-bevacizumab-in-combination-with-oxaliplatin-and-capecitabine-xelox-for-patients-with-metastatic-colorectal-cancer-with-unresectable-liver-metastases-a-phase-ii-open-label-single-arm-noncomparative-trial
#4
Hong-Hwa Chen, Jen-Kou Lin, Joe-Bin Chen, Chieh-Han Chuang, Mei-Ching Liu, Jen-Yi Wang, Chung-Rong Changchien
AIM: This phase II, open-label study evaluated the efficacy and safety of neoadjuvant therapy with bevacizumab plus XELOX (capecitabine and oxaliplatin) for untreated metastatic colorectal cancer with unresectable liver metastases and assessed conversion of unresectable to resectable metastases after neoadjuvant treatment. METHODS: Patients received bevacizumab 5 mg/kg and oxaliplatin 85 mg/m(2) on day 1, and capecitabine 1000 mg/m(2) twice daily on days 1-5 followed by 2 days of rest in a 14-day cycle for 12 cycles; bevacizumab was excluded in cycles 6 and 7...
September 14, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28904173/impact-of-metastasectomy-in-the-multimodality-approach-for-braf-v600e-metastatic-colorectal-cancer-the-mayo-clinic-experience
#5
Benny Johnson, Zhaohui Jin, Mark J Truty, Rory L Smoot, David M Nagorney, Michael L Kendrick, Benjamin R Kipp, Axel Grothey
BACKGROUND: BRAF V600E mutations are present in 8%-10% of patients with metastatic colorectal cancer (mCRC) and portend poor prognosis. This study investigated the impact of metastasectomy for patients with BRAF V600E mCRC. Subjects, Materials, and Methods . Using prospective clinical and molecular data, patients with BRAF V600E mCRC were analyzed for clinical characteristics and survival. Statistical analyses utilized the Kaplan-Meier method, log-rank test, and Cox proportional hazard models...
September 13, 2017: Oncologist
https://www.readbyqxmd.com/read/28903452/cytoreductive-surgery-plus-hyperthermic-intraperitoneal-chemotherapy-improves-survival-for-peritoneal-carcinomatosis-from-colorectal-cancer-a-systematic-review-and-meta-analysis-of-current-evidence
#6
REVIEW
Chao-Qun Huang, Yao Min, Shu-Yi Wang, Xiao-Jun Yang, Yang Liu, Bin Xiong, Yutaka Yonemura, Yan Li
OBJECTIVES: The therapeutic efficacy of cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal carcinomatosis (PC) from colorectal cancer (CRC) is still under debate. This meta-analysis and systematic review of published literature on this comprehensive strategy aims to evaluate its efficacy on CRC patients with PC. METHODS: A systemic review with meta-analysis of published literatures on treatment of CRS plus HIPEC for patients with PC from CRC was performed...
August 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28903398/new-perspectives-of-cobalt-tris-bipyridine-system-anti-cancer-effect-and-its-collateral-sensitivity-towards-multidrug-resistant-mdr-cancers
#7
Betty Yuen Kwan Law, Yuan Qing Qu, Simon Wing Fai Mok, Hauwei Liu, Wu Zeng, Yu Han, Flora Gordillo-Martinez, Wai-Kit Chan, Keith Man-Chung Wong, Vincent Kam Wai Wong
Platinating compounds including cisplatin, carboplatin, and oxaliplatin are common chemotherapeutic agents, however, patients developed resistance to these clinical agents after initial therapeutic treatments. Therefore, different approaches have been applied to identify novel therapeutic agents, molecular mechanisms, and targets for overcoming drug resistance. In this study, we have identified a panel of cobalt complexes that were able to specifically induce collateral sensitivity in taxol-resistant and p53-deficient cancer cells...
August 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28902369/synergistic-inhibitory-effects-on-hepatocellular-carcinoma-with-recombinant-human-adenovirus-aspp2-and-oxaliplatin-via-p53-independent-pathway-in-vitro-and-in-vivo
#8
Xiaoni Liu, Jianji Xu, Shuang Wang, Xiaoxiao Yu, Boxin Kou, Mengyin Chai, Yunjin Zang, Dexi Chen
The present study was designed to investigate the synergistic inhibitory effects on hepatocellular carcinoma with recombinant human adenovirus Aspp2 (Aspp2-ad) and oxaliplatin via p53-independent pathway in vitro and in vivo. After being treated with Aspp2-ad and/or oxaliplatin for 24-48 h, HepG2P53-/- and Hep3B cells showed a significant growth inhibition compared with vehicle control. Combination group showed a synergetic effect, the inhibitory rates were all above 80% at 48 h point in HepG2P53-/- and Hep3B cells...
August 29, 2017: International Journal of Oncology
https://www.readbyqxmd.com/read/28900996/-clinicopathologic-characteristics-and-prognosis-of-gastric-hepatoid-adenocarcinoma
#9
Rongfei Zhao, Xinxin Wang, Xin Lan, Mingsen Li
OBJECTIVE: To investigate the clinicopathological characteristics, diagnosis, treatment and prognosis of gastric hepatoid adenocarcinoma(HAS). METHODS: Retrospective analysis of clinicopathological data of 24 cases with gastric HAS diagnosed by surgery and pathology in Chinese PLA General Hospital from January 2013 to May 2016 were carried out. All the patients underwent preoperative serum alpha fetoprotein (AFP), carcinoembryonic antigen (CEA), endoscopy and imaging examination (CT or B-mode ultrasonography), and those with elevated AFP were excluded from liver cancer, cirrhosis, endodermal sinus tumor and other diseases...
September 25, 2017: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/28900843/pressurized-intraperitoneal-aerosol-chemotherapy-pipac-procedure-for-non-resectable-peritoneal-carcinomatosis-with-video
#10
Jean-Baptiste Cazauran, Mohammad Alyami, Antoinette Lasseur, Isabo Gybels, Olivier Glehen, Naoual Bakrin
BACKGROUND: Peritoneal carcinomatosis (PC) is a common evolution of abdominal cancers and is associated with poor prognosis in the absence of aggressive multimodal therapy.1 Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a safe and innovative approach, which enhances the effect of chemotherapy 2 without reported renal/hepatic toxicity.3,4 It requires mastery of technical aspects to reduce postoperative morbidity, increase effectiveness, and prevent caregiver chemotherapy exposure...
September 12, 2017: Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract
https://www.readbyqxmd.com/read/28894576/first-line-chemotherapy-with-capecitabine-oxaliplatin-for-advanced-gastric-cancer-a-phase-i-study
#11
Hironaga Satake, Hisateru Yasui, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Masahito Kotaka, Takeshi Kato, Akihito Tsuji
Combination chemotherapy with capecitabine and oxaliplatin for gastric cancer (G-XELOX) is considered as a potentially promising regimen. However, the use of the G-XELOX regimen in Japanese patients has not been investigated to date, and recommended doses of G-XELOX for Japanese patients with metastatic gastric cancer have not been established. The aim of the present study was to determine the maximum tolerated dose (MTD) and recommended dose (RD) for systemic chemotherapy with G-XELOX for metastatic gastric cancer...
September 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28888554/how-to-treat-pancreatic-adenocarcinoma-in-elderly-how-far-can-we-go-in-2017
#12
REVIEW
Marine Gilabert, Jean Luc Raoul, Frederique Rousseau
Pancreatic adenocarcinoma is one of the most fatal cancers that frequently affects older patients. Limited data suggest that older patients are as likely to benefit from surgery, radiation, and chemotherapy as younger patients. The only potentially curative approach for pancreatic cancer is surgery but this is only performed in less than 20% of patients considered resectable. With improvements in surgical techniques, older patients without major comorbidities show a course of disease after resection similar to that of younger patients...
September 6, 2017: Journal of Geriatric Oncology
https://www.readbyqxmd.com/read/28884391/prognostic-significance-of-surgical-margin-size-after-neoadjuvant-folfox-and-or-folfiri-for-colorectal-liver-metastases
#13
Cynthia L Miller, Martin S Taylor, Motaz Qadan, Vikram Deshpande, Steven Worthington, Robert Smalley, Chey Collura, David P Ryan, Jill N Allen, Lawrence S Blaszkowsky, Jeffrey W Clark, Janet E Murphy, Aparna R Parikh, David Berger, Kenneth K Tanabe, Keith D Lillemoe, Cristina R Ferrone
PURPOSE: Optimal margin size when resecting colorectal liver metastases (CRLM) remains unclear, particularly in the setting of perioperative chemotherapy. We evaluated the prognostic significance of margin size in patients who received neoadjuvant FOLFOX and/or FOLFIRI prior to resection of CRLM. METHODS: Clinicopathologic factors were collected for patients who underwent curative liver resections for CRLM between 4/2004-1/2016 and received neoadjuvant oxaliplatin and/or irinotecan and 5-FU (FOLFOX, FOLFIRI)...
September 7, 2017: Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract
https://www.readbyqxmd.com/read/28884286/combination-of-irinotecan-oxaliplatin-and-5-fluorouracil-as-a-rechallenge-regimen-for-heavily-pretreated-metastatic-colorectal-cancer-patients
#14
Gustavo Dos Santos Fernandes, Maria Ignez Braghiroli, Michelle Artioli, Ana Carolina Carvalho Rocha Paterlini, Marcela Crosara Teixeira, Brenda Pires Gumz, Daniel da Motta Girardi, Oddone F M Braghiroli, Frederico Perego Costa, Paulo M Hoff
PURPOSE: Our objective was to evaluate the benefit of re-exposing patients with refractory metastatic colorectal cancer (mCRC) to a combination of oxaliplatin, irinotecan and 5-fluorouracil treatment. METHODS: We retrospectively analysed patients with mCRC who received a combination of oxaliplatin, irinotecan and fluorouracil as a rechallenge regimen after progressing on the same drugs. Both FOLFOXIRI and FOLFIRINOX were used. Toxicity was evaluated for each treatment cycle, and survival analysis was performed using the Kaplan-Meier method...
September 8, 2017: Journal of Gastrointestinal Cancer
https://www.readbyqxmd.com/read/28883618/cg200745-an-hdac-inhibitor-induces-anti-tumour-effects-in-cholangiocarcinoma-cell-lines-via-mirnas-targeting-the-hippo-pathway
#15
Dawoon E Jung, Soo Been Park, Kahee Kim, Chanyang Kim, Si Young Song
Cholangiocarcinoma is a devastating malignancy with fatal complications that exhibits low response and resistance to chemotherapy. Here, we evaluated the anticancer effects of CG200745, a novel histone deacetylase inhibitor, either alone or in combination with standard chemotherapy drugs in cholangiocarcinoma cells. CG200745 dose-dependently reduced the viability of cholangiocarcinoma cells in vitro and decreased tumour volume and weight in a xenograft model. Administering CG200745 along with other chemotherapeutic agents including gemcitabine, 5-fluorouracil (5-FU), cisplatin, oxaliplatin, or gemcitabine plus cisplatin further decreased cholangiocarcinoma cell viability, with a combination index < 1 that indicated synergistic action...
September 7, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28881609/grape-seed-extracts-modify-the-outcome-of-oxaliplatin-in-colon-cancer-cells-by-interfering-with-cellular-mechanisms-of-drug-cytotoxicity
#16
Letizia Porcelli, Rosa Maria Iacobazzi, Anna Elisa Quatrale, Carlo Bergamini, Nunzio Denora, Pasquale Crupi, Donato Antonacci, Anita Mangia, Giovanni Simone, Nicola Silvestris, Amalia Azzariti
Grape seed extracts are commonly utilized as dietary supplements for their antioxidant properties, even from cancer patients. However, whether these natural extracts interfere with chemotherapeutics utilized in colon cancer treatment is still poorly investigated. The cytotoxicity of extracts from Italia and Palieri cultivars either alone or in combination with oxaliplatin was evaluated in colon cancer cells. Grape seed extracts displayed anti-proliferative activity depending on the concentration utilized through apoptosis induction...
August 1, 2017: Oncotarget
https://www.readbyqxmd.com/read/28881481/oxaliplatin-induces-muscle-loss-and-muscle-specific-molecular-changes-in-mice
#17
Claire E Feather, Justin G Lees, Preet G S Makker, David Goldstein, John B Kwok, Gila Moalem-Taylor, Patsie Polly
INTRODUCTION: Muscle wasting is a frequent, debilitating complication of cancer. The impact of colorectal cancer chemotherapeutic oxaliplatin on the development of muscle loss and associated molecular changes is of clinical importance. METHODS: C57BL/6J male mice were treated with oxaliplatin. Total body weights were measured and behavioral studies performed. Hindlimb muscle weights (gastrocnemius and soleus) were recorded in conjunction with gene and protein expression analysis...
September 7, 2017: Muscle & Nerve
https://www.readbyqxmd.com/read/28881477/multimodal-quantitative-examination-of-nerve-function-in-colorectal-cancer-patients-prior-to-chemotherapy
#18
Tejaswi Kandula, Michelle A Farrar, Arun V Krishnan, Jenna Murray, Hannah C Timmins, David Goldstein, Cindy S-Y Lin, Matthew C Kiernan, Susanna B Park
INTRODUCTION: Given recent findings of subclinical sensory deficits in colorectal cancer patients prior to oxaliplatin treatment, the current study aimed to identify evidence of subclinical peripheral neuropathy on multimodal testing before chemotherapy commencement. METHODS: Clinical, functional and neurophysiological assessments were undertaken in 93 colorectal cancer patients prior to chemotherapy. RESULTS: There was no neurophysiological evidence of neuropathy, with 92/93 sural sensory values within normative reference values for age and no significant abnormalities detected in nerve conduction or nerve excitability studies...
September 7, 2017: Muscle & Nerve
https://www.readbyqxmd.com/read/28881381/muscle-mass-at-the-time-of-diagnosis-of-nonmetastatic-colon-cancer-and-early-discontinuation-of-chemotherapy-delays-and-dose-reductions-on-adjuvant-folfox-the-c-scans-study
#19
Elizabeth M Cespedes Feliciano, Valerie S Lee, Carla M Prado, Jeffrey A Meyerhardt, Stacey Alexeeff, Candyce H Kroenke, Jingjie Xiao, Adrienne L Castillo, Bette J Caan
BACKGROUND: For many chemotherapy regimens dosed based on body surface area (BSA), patients experience dose reductions or delays or discontinue treatment, thereby reducing survival. Consideration of body composition may be useful in individualizing chemotherapy dosing, but to the authors' knowledge few studies to date have examined the association of body composition with chemotherapy tolerance in patients with colon cancer. METHODS: The authors identified patients with nonmetastatic colon cancer who were diagnosed from 2006 through 2011 at Kaiser Permanente and who received leucovorin calcium/calcium folinate, 5-fluorouracil, and oxaliplatin (FOLFOX) as initial adjuvant chemotherapy (533 patients)...
September 7, 2017: Cancer
https://www.readbyqxmd.com/read/28881354/preoperative-capecitabine-oxaliplatin-and-irinotecan-in-resectable-gastric-or-gastroesophageal-junction-cancer-pathological-response-as-primary-endpoint-and-fdg-pet-predictions
#20
Rosa Berenato, Federica Morano, Filippo Pietrantonio, Christian Cotsoglou, Marta Caporale, Gabriele Infante, Alessandro Pellegrinelli, Alessandra Alessi, Carlo Battiston, Jorgelina Coppa, Barbara Padovano, Alessia Mennitto, Monica Niger, Giovanni Fucà, Silvia Lazzati, Giorgio Greco, Gabriele Delconte, Filippo de Braud, Vincenzo Mazzaferro, Maria Di Bartolomeo
OBJECTIVES: This phase II trial was aimed at assessing the safety and activity of capecitabine, oxaliplatin, and irinotecan (COI regimen) as a preoperative treatment for resectable gastric cancer (GC) or gastroesophageal junction (GEJ) cancer. METHODS: Patients affected by T3-T4/N0-N+/M0 GC/GEJ cancer were treated with the COI regimen for 4 cycles followed by restaging and gastroresection with D2 lymphadenectomy. Four postoperative cycles were scheduled. The primary endpoint was pathological response rate according to Becker et al...
September 8, 2017: Oncology
keyword
keyword
73953
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"